BACKGROUND: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …

Abstract Background In Non-small cell lung cancer (NSCLC), an overactive epidermal
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …

PURPOSE: Erlotinib is the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) which has demonstrated a survival benefit in non-small-cell lung cancer …

Background: This phase II study evaluated efficacy of first-line erlotinib therapy for chemo-
naïve patients with non-small cell lung cancer (NSCLC) by their clinicopathological and/or …

INTRODUCTION: Some patients with advanced NSCLC show prolonged disease
stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is …

Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …

Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …

Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …

Purpose Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …

Objective Erlotinib has been reported to be useful for treatment of non-small-cell lung cancer
harboring mutation of the epidermal growth factor receptor gene EGFR-mt. However, no …